Prothena to Report Third Quarter 2022 Financial Results on November 3rd
27 oct. 2022 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on...
Prothena to Participate in Upcoming Healthcare Conferences
01 sept. 2022 16h20 HE
|
Prothena Corporation plc
DUBLIN, Ireland, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built...
Prothena Announces Appointment of Biotechnology Industry Leader Helen S. Kim to its Board of Directors
01 sept. 2022 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built...
Prothena Reports Second Quarter 2022 Financial Results and Business Highlights
08 août 2022 16h05 HE
|
Prothena Corporation plc
Net cash used in operating and investing activities was $35.5 million in the second quarter and $72.9 million for the first six months of 2022; quarter-end cash and restricted cash position was $510.1...
Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 août 2022 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of novel investigational therapeutics...
Prothena to Report Second Quarter 2022 Financial Results on August 8th
01 août 2022 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on...
Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 juil. 2022 16h16 HE
|
Prothena Corporation plc
DUBLIN, Ireland, July 01, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of novel investigational therapeutics...
Prothena to Participate in Jefferies Healthcare Conference
02 juin 2022 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, June 02, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on...
Prothena Reports First Quarter 2022 Financial Results and Business Highlights
05 mai 2022 16h05 HE
|
Prothena Corporation plc
Net cash used in operating and investing activities was $37.4 million in the first quarter; quarter-end cash and restricted cash position was $544.3 millionAdvanced PRX012, a potential best-in-class,...
Prothena to Report First Quarter 2022 Financial Results on May 5th
28 avr. 2022 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, April 28, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built...